secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2025-01-29T23:59:59+00:00
Accession:  0001104659-25-007198
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome launches public offering of common stock; pipeline update with Phase 3 data H2 2025
--------------------------------------------------------------------------------

- Underwritten public offering of common stock commenced; size not disclosed.
- Preliminary cash, equivalents and marketable securities $217.3M as of Dec 31, 2024.
- Varegacestat Phase 3 desmoid tumor trial fully enrolled; topline data expected H2 2025.
- IM-1021 (ROR1 ADC) IND cleared Dec 2024; Phase 1 starts Q1 2025 at 2 mg/kg starting dose.
- IM-3050 (FAP RLT) IND submission expected Q1 2025; three ADCs in IND-enabling manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465925007198/0001104659-25-007198-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465925007198/tm254675d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-007198

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer